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Summary: 
Graft-versus-host disease (GVHD) is a serious complication after allogeneic stem cell 
transplantation, the mechanism of it is still not elucidated. Recent findings suggest 
that host endothelial cells are a target of alloreactive donor cytotoxic T lymphocytes 
in GVHD and tissue factor(TF) plays an important role not only in 
coagulation-inflammation cycle, but also in transplant immunology. We postulate TF 
expression in vascular endothelial cells(VEC) may play an pivotal role in the 
pathogenesis of GVHD. TF gene andprotein expression in target organs of GVHD in 
aGVHD mice was significantly elevated compared to that of controls as determined 
by real-time PCR and Western blotting. Allogeneic CD4+T cell and CD8+T cells 
enhanced TF, VCAM-1, TNF-α, IFN-γ and IL-6 expression in TNF-α prestimulated 
HUVECs compared to controls as determined by flowcytometry and real-time PCR. 
JNK and p38MAPK mediated allogeneic T cells-induced TF expression in HUVECs. 
These effects were largely prevented by monoclonal antibody against TF, SB203580 
and SP600125. In concert, these data provide strong evidence that upregulated TF 
expression is related to tissue damage caused by GVHD, TF isthe key factor in 
GVHD mediated by endothelial cells and allogeneic T cells-induced TF and 
consecutive proinflammatory cytokines expression in VEC contribute to the 
pathogenesis of GVHD. 
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Introduction 
Graft-versus-host disease (GVHD) is a serious complication after allogeneicstem 
cell transplantation(SCT). It is also a major cause of early and late morbidity and 
mortality in allogeneic SCT recipients[1]. Although the molecular pathogenesis of 
GVHD remains to be uncovered, there is a general agreement that infiltrating T 
lymphocytes play a central role and proinflammatory cytokines including IFN-γ,IL-6 
and TNF-α are important mediators and regulators of GVHD [2,3,4]. 
After allogeneic SCT, vascular endothelial cells are the first allogeneic recipient 
cells encountered by circulating immunocompetent donor T cells. Host endothelial 
cells are a target of alloreactive donor cytotoxic T lymphocytes in GVHD[5,6]. 
Vascular injury has been described in patients with acute and chronicGVHD. The 
markers of vascular injury including vWF, endothelial adhesion molecules (VCAM-1, 
E-selectin and ICAM-1), vascular growth factor, endothelial cell in circulation are 
proved to be highly related to GVHD[7,8,9].  
Allogeneic T cell can induce tissue factor(TF) expression in vascular endothelial 
cell(VEC)[10,11]. TF is a transmembrane protein present on the surface of activated 
cells and a member of the class II cytokine and hematopoietic growth factor receptor 
family[12]. Much recent data shows TF activity is important not only in 
coagulation-inflammation cycle, but also in regulating the release ofproinflammatory 
cytokines during the course of inflammation through intracellular signal transduction 
pathway. TF expression in VEC is upregulated post-injury and activation. And VEC 
is the main source of TF in vivo[13]. 
We postulate enhanced TF expression in VEC may play an pivotal role inthe 
pathogenesis of GVHD. To ascertain this speculation, we investigated TF mRNA and 
protein expression in organs of aGVHD mice and controls and theeffect of allogeneic 
T cells on TF,VCAM-1,TNF-α,IFN-γ and IL-6 expression and activation of MAPKs 
in HUVECs. 
Materials and methods 
Mice 
Eight- to 12-week-old female BALB/c(H2－Kd) and male C57BL/6 (H-2b) 
wild-type mice were purchased from Beijing Vital River Laboratory Animal 
Co.These studies were conducted in accordance with principles set forth in the Guide 
for Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, 
National Research Council. 
Reagent 
FITC conjugated H-2Kb+ monoclonal antibody and PE conjugated H-2Kd+ 
monoclonal antibody were from BD Pharmingen(San Jose，CA); Protein assay, SYBR 
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Green I and AmpliTaq DNA Polymerase were from BioRad (CA, USA);M-MLV 
Reverse Transcriptase were from Invitrogen (Carlsbad, CA); FITC conjugated 
TF,VCAM-1,IgG2a monoclonal antibody(human) were from American Diagnostica 
Inc.; goat anti-mice TF monoclonal antibody, p38MAPK and phospho-p38MAPK 
monoclonal antibody, JNK and phospho － JNK monoclonal antibody,ERK and 
phospho-ERK monoclonal antibody, TNF-α(Santa Cruz, CA, USA); inhibitor of 
p38MAPK(SB203580) and inhibitor of JNK(SP600125) were from Alexis 
Biochemicals(CA, USA). 
Induction of acute GVHD 
After lethally irradiated with 8.5 Gy total body irradiation (TBI) using an X ray 
source, female BALB/c recipient mice (15 mice in each group) were intravenously 
injected (IV) with 1×107 BM cells and 1×107 splenic T cells from BALB/c (syngeneic) 
and C57BL/6(allogeneic) donors on day 0 respectively. Mice were kept on antibiotic 
water (250 μg/ml erythromycin and 320 μg/ml gentamycin;) for the first 28 days and 
5 days before transplantation. The survival and appearance of mice were monitored 
daily after SCT. Donor cell engraftment was determined by flow cytometric analysis 
of the percentage of H-2Kb+ and H-2Kd+ cells with the relevant monoclonal antibodies 
in the spleen cells on 14 days and 21 days after SCT. The degree of clinical GVHD 
was assessed bya scoring system described by Cooke et al[14]. that sums changes in 
five clinical parameters: weight loss, posture, activity, fur texture and skin integrity 
(maximum index=10). 
The allogeneic SCT mice were killed when they showed typical GVHD 
signs(GVHD score≥8), syngeneic SCT mice were killed 3 or 4 weeks after SCT, and 
the ear skin, liver, small intestine, stomach, lung, kidney were subjectedto 
histopathological examination, quantitative real-time PCR and Western blotting 
analysis. 
Histologic examination 
The organs were fixed with 4% neutral buffered formalin, and embedded in 
paraffin. After the thin tissue sections had been deparaffinized on glass slides, 
samples were stained with hematoxylin and eosin. 
Cell isolation and cell cultures 
Human peripheral blood mononuclear cells(PBMC) were separated from healthy 
volunteers using Ficoll-Hypaque gradients. Monocytes were separated by plastic 
adhesion; CD4+T cells or CD8+T cells were isolated from PBMC by positive selection 
using magnetic beads coated with anti-CD4+ or anti-CD8+ antibody(Miltenyi 
Biotech,German) according to the manufacturer’s instructions. Samples of the 
resulting populations were immunostained to check the purity of thepopulation; the 
CD4 and CD8 populations were at least 95% CD4 or CD8 positive. 
Human umbilical vein endothelial cell(HUVEC) and endothelial complete 
medium(ECM) were purchased from Sciencecell Research Laborotory（CA，USA）
and grown according to the supplier’s directions. Cells in passage 3 and 8 were used 
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in all experiments. Eight hours before starting an experiment ECM was removed and 
replaced by the same medium but without FCS, growth factors. Every test used 
HUVECs from at least two different persons and was conducted for three times. 
Coculturing of HUVECs and allogeneic T cells 
1×104 HUVECs were seeded on six-well plates in triplicate and were 
presimulated by TNF-α(1ng/ml) for 4 hours. After thorough washing with ECM, 
1×105 allogeneic CD4+T cells or CD8+T cells were added to HUVECs(ratio 10:1). 
The cells were grown at 37 in a humidified atmosphere containing 5% CO2. To 
detect the effect of TF antibody, SB203580(inhibitor of p38MAPK), 
SP600125(inhibitor of JNK) on allogeneic T cell-induced HUVECs, HUVECs were 
pretreated with TF antibody(20μg/ml), SB203580(10μM), SP600125(30μM) 
seperatedly 30 minutes before coculturing. 
Measurements of TF and VCAM-1 expression on HUVEC membrane by 
flowcytometry 
After coculturing with allogeneic CD4+T cells or CD8+T cells for 0,3,6,12hours, 
HUVECs were removed from the wells with non-enzymatic Cellstripper after being 
washed with cold PBS, and labeled with FITC-TF, FITC-VCAM-1,FITC-IgG2a 
respectively according to manufacturer’s instructions. The percentageof TF and 
VCAM-1 expression was analyzed by flowcytometry.  
Quantitative real-time PCR   
Freshly isolated organs(n =10) were snap-frozen in liquid nitrogen and stored at 
-80 until total RNA extraction. Total RNA of the organs and HUVECs was 
extracted by using TRIzol reagent according to the protocol provided bythe 
manufacturer. Two micrograms of total RNA each probe were reverse transcribed to 
single-strand cDNA using oligo(dT) primer and 20 U MMLV.  
Quantitative real-time PCR was then used to detect TF mRNA in organs of 
aGVHD mice and the controls. TF, TNF-α, IFN-γ, IL-6 mRNA of HUVECswas also 
detected. With 2.5μl of cDNA being incubated in 25μl IQ Supermix containing 
500nM of respective primers, or 50nM of 18S primers used for sample normalization, 
and fluorescence dye SYBR Green Ⅰ. The sequence of primers and condition of 
real-time PCR was given in table 1. The specificity of the amplified products was 
monitoredby means of melting curves at the end of each amplification. Real-time 
RT-PCR was carried out in triplicate for each sample using a 7500 Real-Time PCR 
System(Applied Biosystems, Foster City, CA, USA). 
Assessments of TF expression in the organs and MAPKs activation of HUVEC 
by Western blotting 
After coculturing with allogeneic CD4+T cells or CD8+T cells for 0,15,30,60 
minutes, HUVECs were lysed with nonionic detergent-containing buffer, the 
lysed cells were scraped off the dish using a rubber policeman, the tissues were also 
lysed with nonionic detergent-containing buffer, then transferred to microcentrifuge 
tubes, and vortexed for 10 s. The cell and tissue lysates were centrifuged to remove 
insoluble materials and the protein concentration of each sample was measured. 
Approximately 50μg of supernatant protein from each samplewas used for gel 
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electrophoresis analysis on a 10% SDS-polyacrylamide gel. After electrophoresis, the 
fractionated proteins on gel were transferred to PVDF membranes. After blocking 
with 5% milk overnight, the membrane was incubated overnight with the primary 
antibody separately, then the membranes were extensively washed with TBST and 
incubated for 60 min with the secondary antibody. After extensive washing with 
TBST, the immune complexes were detected by ECL kit (Pierce 
Biotechnology,USA). 
Statistical analysis 
Data are shown as means±SD of three independent experiments. Data were 
analyzed by two-way analysis of variances(ANOVA) using the Statistical Analysis 
System(SAS, Cary, NC). A P-value less than 0.05 was considered significant. 
Results 
The manifestation of aGVHD after allogeneic SCT 
Allogeneic SCT mice showed typical symptoms of aGVHD such as weightloss, 
diarrhea, dermal ulcer, depilate and posture change during 18~28 days after SCT and 
all died in the first 28 days after SCT. Typical histologic changesof aGVHD were 
seen in liver, skin, stomach, small intestine of them. On 14 days and 21 days after 
SCT flowcytometric assay demonstrated over 95% spleencells of allogeneic SCT 
mice were from donors. It verified successful implantation of donor hematopoietic 
stem cells. But there was no clinical and hitologic appearance of aGVHD in the 
controls.  
Upregulation of TF mRNA and protein expression in target organs of aGVHD 
Enhanced TF mRNA expression were seen in the skin, stomach, small intestine, 
liver of aGVHD mice(p<0.001), they were respectively 15.1±2.1，5.5±1.4，9.7±2.3，
14.3±2.9 times higher than controls. There were no difference in the TF mRNA 
expression of the lung and kidney between the two groups(figure 1). The results of TF 
protein expression tested by Western blotting were  inaccord with the results of 
quantitative real-time PCR(figure 2). Protein expression of TF in skin,stomach,small 
intestine,liver of aGVHD mice were respectively 6.1±3.1, 7.2±2.5，8.7±2.3, 10.7±4.9 
times higher than the controls(P<0.01). 
Allogeneic CD4+T cells and CD8+T cells enhance TF, VCAM-1, TNF-α, IFN-γ, 
IL-4 expression in HUVECs 
Flowcytometric assay showed TF、VCAM-1 expression on TNF-α pretreated 
HUVEC membrane are very low. After incubated with allogeneic CD4+T cells or 
CD8+T cells, TF and VCAM-1 expression on HUVEC membrane increased 
significantly(p<0.01), and reached peak value at the 6-h time-point(showed in table 
2,3).  
After coculturing with allogeneic CD4+T cells or CD8+T cells for 3,6,12 hours, 
TF mRNA expression in HUVECs was elevated significantly and reachedpeak value 
at the 3-h time-point; TNF-α,IFN-γ,IL-6 mRNA expression also wasupregulated, and 
reached the peak value at the 6-h time-point(figure 3). 
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Involvement of MAPKs in allogeneic CD4+T cells and CD8+T cells-inducedTF 
expression in HUVECs 
Allogeneic CD4+T cells and CD8+T cells enhanced JNK and p38MAPK 
phosphorylation of HUVECs compared to untreated HUVECs. The increase in JNK 
activation and p38MAPK activation were maximal after 30 minutes of stimulation 
(Figure 4a,4b). The increase in JNK activation after 30 minutes was 67.3-fold for 
allogeneic CD4+T cells(n=9; p<0.0001) and 78.9-fold for allogeneic CD8+T 
cells(n=9;p<0.0001); the increase in p38MAPK activation after 30 minutes was 
54.6-fold for allogeneic CD4+T cells(n=9; p<0.0001) and 62.3-fold for allogeneic 
CD8+T cells(n=9; p<0.0001). Expression of total JNK, p38MAPK,ERK and 
phosphorylated ERK were not affected. 
SB203580, a specific inhibitor of p38MAPK, reduced allogeneic CD4+T cells 
and CD8+T cells-induced TF expression on HUVEC membrane by 39.9±4.3% 
(p<0.05) and 64.4±6.1% (p<0.01); SP600125 a specific inhibitor of JNK reduced 
allogeneic CD4+T cells and CD8+T cells–induced  TF expression on HUVEC 
membrane by 66.1±5.2% and 6.8±3.4% (n=9; P<0.01;Table 4). AllogeneicCD4+T 
cells and CD8+T cells induced TF mRNA expression in HUVECs was also decreased 
by SP600125 and SB203580 (p<0.01). Data are expressed as fold induction relative to 
cytokine expression by non-induced HUVEC (Figure 4c). 
The effect of monoclonal antibody against TF, SB203580, SP600125 on allogeneic 
T cells-induced cytokines expression of HUVECs 
Mice anti-human TF monoclonal antibody(American Diagnostica Inc.) is the 
neutralizing antibody of TF[15]. HUVECs were pretreated with TF antibody, 
SP600125, SB203580 30 minutes before stimulation with T cells. At t=6h, allogeneic 
T cells-induced VCAM-1 expression on HUVECs membrane was decreased 
compared with non-treated HUVEC (Table 4), allogeneic T cells-induced TNF-α, 
IFN-γ, IL-6 mRNA expression in HUVECs was also downregulated by TF antibody, 
SB203580, SP600125 compared with non-treated HUVECs(Figure 5). 
Discussion 
In the present study, a model of murine aGVHD after allogeneic SCT was 
established. To exclude the influence of conditioning regimen, syngeneic SCTmice 
were used as controls. TF mRNA and protein expression were enhanced specifically 
in target organs of GVHD including skin, liver, stomach, smallintestine. These data 
indicates that upregulation of TF expression is related to tissue damage caused by 
GVHD. Because there are abundant vascular beds in these organs, and TF expression 
of VECs upregulates post injury and activation, we postulate that upregulated TF 
expression of VEC may contribute to tissue injury caused by GVHD. 
To verify this speculation, we cocultured allogeneic CD4+T cells and CD8+T 
cells with TNF-α prestimulated HUVECs. The results demonstrate that allogeneic 
CD4+T cells and CD8+T cells lead to upregulation of TF, VCAM-1 and 
proinflammatory cytokines(including TNF-α，IFN-γ, IL-6) expression in HUVECs as 
determined by FCM and real-time PCR. And these effects can be preventedby 
monoclonal antibody against TF, inhibitor of p38MAPK, and inhibitor of JNK. 
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Much research of recent years provide the evidence that TF is involved in 
transplant immunology. Naji,et al[16] pointed out that donor specific antibody can 
induce TF overexpression in VEC. Schmid,et al[11] reportted that after coculturingwith 
allogeneic CD4+T cells and CD8+T cells, TF mRNA and protein expression in VEC 
increased significantly. Significantly higher levels of microparticles (containing TF) 
from endothelial cells were observed in patients with acute GVHD, in contrast, 
neither the conditioning regimen nor infectious complications influenced the level of 
these microparticles[17]. 
It is clearly explicated that VCAM-1 expression in target organs of GVHD 
increased and enhanced expression of VCAM-1 is correlated to donor T 
cellinfiltration[18]. Much data shows TNF-α，IFN-γ, IL-6 are important markers of 
GVHD[19]. Enhanced TF expression in VEC is induced by proinflammatory cytokines 
that are secreted by T cells, which in turn contribute to cytokine generation or 
inflammatory cell apoptosis through intracelluar signal transduction[12,20,21]. So 
allogeneic T cells-induced TF and consecutive proinflammatory cytokinesexpression 
in VEC may contribute to the pathogenesis of GVHD. TF is the key factor in GVHD 
mediated by VEC, measures which block TF expression inVEC may inhibit 
production of proinflammatory cytokines and donor T cells infiltration contributing to 
GVHD and alleviate GVHD. Furthermore, there is increasing evidence of the 
existence of an endothelial form of graft-versus-host disease, VEC injury is closely 
related to tissue damage caused by GVHD[22]，measures to ameliorate VEC injury 
may separate GVHD from the beneficial graft-versus-leukaemia effect.  
 The mitogen-activated protein kinases (MAPKs), play an essential role in 
regulating several intracellular processes, such as gene expression, growth, cell 
survival, differentiation or death[23,24].To further explore the mechanisms of allogeneic 
T cells-induced TF expression in HUVECs, Western blotting was applied 
to measure the phosphorylation of three members of the MAPK family (ERK, JNK, 
p38 MAPK). Our results demonstrate that allogeneic T cells activate the 
phosphorylation of JNK and p38MAPK, and inhibition of p38 MAPK and 
JNK,significantly prevent allogeneic T cells-induced TF, VCAM-1 and 
proinflammatory cytokines expression. These data suggest targeting JNK and 
p38MAPK pathway may be valuable in designing new therapy modalities for treating 
GVHD. 
In conclusion, this preliminary study indicates that enhanced TF expressionof 
VEC plays an important role in the pathogenesis of tissue damage caused by GVHD, 
and measures to block TF expression in VEC including monoclonal antibody against 
TF, inhibitor of p38MAPK and JNK can interrupt TF mediated inflammation, thus 
may ameliorate GVHD. These data lead to better understanding of the mechanisms of 
GVHD and may provide a new target for treatment of GVHD. 
Reference 
1. Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson
8 
8 
C, et al. Long-term survival and late deaths after allogeneic bone marrow trans
plantation. Late Effects Working Committee of the International Bone Marrow 
Transplant Registry. The New England Journal of Medicine 1999; 341(1): 14–2
1. 
2. Visentainer JE, Lieber SR, Persoli LB, Vigorito AC, Aranha FJ, de Brito Ei
d KA, et al. Serum cytokine levels and acute graft-versus-host disease after H
LA-identical hematopoietic stem cell transplantation. Exp Hematol 2003;31(11):1
044–50. 
3. Nomura S, Ishii K, Inami N, Uoshima N, Ishida H, Yoshihara T,et al.Role 
of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations
 after stem cell transplantation. Transplant Immunology 2007;18 (2):115–121. 
4. Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Cam
p B, etal. Proinflammatory cytokines and theirrole in the developmentof major 
transplant-related complications in the earlyphase after allogeneicbone marrow tr
ansplantation. Leukemia 2003;17(6):1150–6. 
5. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, PoberJS, et
 al.Endothelial injury mediated by cytotoxic T lymphocytes and loss of microv
essels in chronic graft versus host disease. Lancet 2002;359(9323):2078–83. 
6.Tichelli A,Gratwohl A.Vascular endothelium as ‘novel’ target of graft-versus-h
ost disease. Best Pract Res Clin Haematol 2008;21(2):139-48.  
7.Tesfamariam B, DeFelice AF. Endothelial injury in the initiation and progress
ion of vascular disorders. Vascul Pharmacol.2007;46(4):229–237. 
8.Goon PK, Boos CJ,Lip GY. Circulating endothelial cells: markers of vascular
dysfunction. Clin Lab 2005; 51(9-10):531–538. 
9. Pihusch V, Rank A, Steber R, Pihusch M, Pihusch R, Toth B,et al. Endothe
lial cell-derived microparticles in allogeneic hematopoietic.stem cell recipients. T
ransplantation 2006;81(10):1405–1409. 
10.Reverdiau-Moalic P,Watier H,Iochmann S.Human allogeneic lymphocytestrigg
er endothelial cell tissue factor expression by a tumor necrosis factor-dependent
 pathway.Lab Clin Med 1998 Dec:132(6)530-40. 
11. Schmid E, Müller TH, Budzinski RM, Pfizenmaier K, Binder K.Lymphocyt
e adhesion to human endothelial cells induces tissue factor expression via a ju
xtacrine pathway.Thromb Haemost 1995;73(3):421-8. 
12.Spek CA.Tissue factor:from ‘just one of the coagulation factors’ to a major 
player in physiology.Blood Coagulation and Fibrinolysis 2004;15 (suppl1):S3-1
0. 
13.Chu AJ.Tissue factor mediates IFNlammation.Archives of Biochemistry and B
iophysics 2005;440(2):123–132. 
14. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, CrawfordJM, 
et al. An experimental model of idiopathicpneumonia syndrome after bone marr
ow transplantation:1.The roles of minor H antigens and endotoxin.Blood.1996;88
(8):3230-9. 
15. Magdolen V, Albrecht S, Kotzsch M, Haller C, Bürgle M, Jacob U, etal.I
mmunological and functional analyses of the extracellular domain of human tiss
9 
9 
ue factor.Biological chemistry 1998;379(2): 157-65. 
16. Naji A, Deschaseaux F, Racadot E, Ferrand C, Justrabo E, Guignier F,et a
l.Induction of tissue factor expression on human umbilical vein endothelial cells
 by cell-specific HLA class  antibody: preliminary data.Transplant Proceeding
 2005;37(6):2892-3. 
17. Pihusch V, Rank A, Steber R, Pihusch M, Pihusch R, Toth B, et al. Endo
thelial cell-derived microparticles in allogeneic hematopoietic stem cell recipient
s. Transplantation 2006; 81(10):1405–1409. 
18. Eyrich M, Burger G, Marquardt K, Budach W, Schilbach K, Niethammer D,
et al.Sequential expression of adhesion and costimulatory molecules in graft-ver
sus-host disease target organs after murinebone marrow transplantation across m
inorhistocompatibility antigen barriers.Biology of Blood andMarrow Transplantat
ion 2005;11(5):371-82. 
19. Nomura S, Ishii K, Inami N, Kimura Y, Uoshima N, Ishida H, et al.Evalu
ation of Angiopoietins and Cell-Derived Microparticles after Stem Cell Transpla
ntation. Biol Blood Marrow Transplant. 2008;14(7):766-74. 
20. Tang XL, Jiang ZY, Dong J, Liu XC, Cai SY, Xiao R,et al.Expressionof t
issue factor induced by IL-6 in HUVEC.Sichuan Da Xue Xue Bao Yi Xue Ban.
 2006 ;37(2):234-7.   
21. Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, et 
al.Induction of permeability across endothelial cell monolayers by tumor necrosi
s factor(TNF) occurs via a tissue factor-dependent mechanism:relationship betwe
en the procoagulant and permeability effects of TNF.Blood2002;100(4):1334-9. 
22.Biedermann BC.Vascular endothelium and graft-versus-host disease. Best Pract
 Res Clin Haematol 2008;21(2):129-38.  
23.Barr RK, Bogoyevitch MA. The c-Jun N-terminal protein kinase family of 
mitogen-activated protein kinases (JNKMAPKs). Int J Biochem Cell Biol2001;3
3(11):1047-63.  
24. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman 
K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and phy
siological functions.Endocr Rev 2001;22(2):153-83. 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Sequences of primers, condition of real-time PCR 
Gene Sequence of primer Condition  of  PCR 
TF 
(murine) 
β-actin 
(murine) 
TF 
(human) 
TNF-α 
(human) 
IFN-γ 
(human) 
IL-6 
(human) 
β-actin 
(human) 
Sense 5’-GGCAACCCAAACCCACCAAC -3’ 
Antisense 5’- CCCAGGTCACATCCTTCACG -3’ 
Sense 5’- CTCTTTGATGTCACGCACGATTTC -3’ 
Antisense 5’- CTGTCCCTGTATGCCTCTGGTC -3’ 
Sense 5’-CACCTTACCTGGAGACAAACC -3’ 
Antisense5’- GAGGGAATCACTGCTTGAACAC -3’ 
Sense 5’-AACGGCATGTCTCTCAA -3’ 
Antisense 5’- AGTCGGTCACCTTTCT -3’ 
Sense 5’- GACAACCAGGCCATCC -3’ 
Antisense 5’-CAAAACAGCACCGACT -3’ 
Sense 5’-CTCCTATCACTGACGGT -3’ 
Antisense 5’-ATTCACATTGCAGCTCT -3’ 
Sense 5-CGAAACTACCTTCAACTCCATCA-3’ 
Antisense 5’-CGGACTCGTCATACTCCTGCT -3’ 
9530s 
5840s  7230s 
9530s 
5740s  721min 
9530s 
5840s  7230s 
9430s 
6040s  721min 
9430s 
5840s  7230s 
9430s 
6140s  7240s 
9530s 
5840s  7230s 
Table 2 TF expression on HUVECs membrane 
﹡Statistically significant vs. non-treated HUVEC(p<0.05) 
 
Table 3 VCAM-1 expression on HUVECs membrane 
 0h(%HUVEC) 3h(% HUVEC) 6h(% HUVEC) 12h(% HUVEC) 
CD4+ T cells 
CD8+ T cells 
4.2±1.4 
3.8±1.7 
9.3±2.6﹡ 
6.9±3.3 
34.5±9.1﹡ 
14.6±5.7﹡ 
15.7±3.8﹡ 
4.6±1.8 
 0h(%HUVEC) 3h(% HUVEC) 6h(%HUVEC) 12h(%HUVEC) 
11 
11 
﹡Statistically significant vs. non-treated HUVEC(p<0.05) 
 
Table 4 The effect of SB203580 ,SP600125，TF antibody on allogeneic T 
cells-induced TF, VCAM-1 expression on HUVEC membrane. 
◆Statistically significant vs. non-treated HUVEC(p<0.05) ▲Statistically 
significant vs. non-treated HUVEC(p<0.01) 
Titles and legends to figures： 
Figure 1 Expression of TF mRNA in tissues of aGVHD mice and controls.▲ 
p<0.001, aGVHD group vs. controls. 
 
Figure 2 Protein expression of TF in the skin, small intestine, liver, lung,kidne
y and stomach of aGVHD mice(lane 4,5,6,10,11,12) and respective organs of c
ontrols(lane 1,2,3,7,8,9). Enhanced protein expression of TF were seenin the ski
n, small intestine, liver, stomach of aGVHD mice(lane 4,5,6,12)compared to the
 respective tissues of controls(lane 1,2,3,11),p<0.01. 
 
CD4+ T cells 
CD8+ T cells 
3.3±2.1 
2.8±1.4 
19.3±4.8﹡ 
24.9±2.4﹡ 
67.5±10.6﹡ 
57.6±8.3﹡ 
16.8±3.2﹡ 
14.6±4.5﹡ 
 SB203580 SP600125 抗 TF
抗体 
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Figure 3 Effect of allogeneic CD4+T cell(3a) and allogeneic CD8+T cell (3b) o
n TF, TNF-α，IFN-γ and IL-4 mRNA expression in HUVECs. Data are express
ed as fold induction relative to cytokines expression by non-induced HUVECs.
At 3,6,12h time-point, TF, TNF-α，IFN-γ and IL-4 mRNA expression in alloge
neic CD4+T cell and allogeneic CD8+T cell-HUVECs are significantly elevated 
(p<0.05, compared to controls). 
 
Figure 4 JNK and  p38MAPK mediate the effect of allogeneic CD4+T cell an
d  CD8+T cell on TF expression. Figure 4a,4b respectively show the effect of 
allogeneic CD4+T cell(a) and  CD8+T cell(b) on  MAPK expression of HUVE
C. Allogeneic CD4+T cell and  CD8+T cell enhance JNK and  p38MAPK pho
sphorylation of HUVEC(p<0.0001,compared to TNF-α prestimulated HUVEC). 
Expression of total JNK,p38MAPK,ERK and phosphorylationof ERK are not af
fected. In the presence of SP600125 or SB203580(4c)，allogeneic CD4+T cell a
nd CD8+T cell-induced TF expression are significantlyblunted.△ p<0.01,compare
d to non-treated HUVEC. 
 
Figure 5 Effect of TF antibody, SB203580, SP600125 on allogeneic CD4+T cel
l and CD8+T cell-induced cytokines expression in HUVECs.In the presence of 
TF antibody, SB203580 and SP600125, allogeneic CD4+T cell and CD8+T cell-
induced TNF-α, IFN-γ, IL-4 expression decrease significantly. Dataare expressed
 as fold induction relative to cytokines expression by TNF-α prestimulated HU
VEC. △p<0.01, compared to non-treated HUVECs ﹡p<0.05, compared to non-tre
ated HUVEC. 
 
 
 





